Minimally invasive surgery is here to stay as patients enjoy briefer recovery times--and payers benefit from lower associated costs. But as the incisions get smaller, visualization gets tougher. That's where surgical photonics company Invuity steps in.
After shunning public attention for more than a year, cancer immunotherapy startup Flexus Biosciences is ready for the limelight now that it is headed toward the clinic, has banked its first two venture rounds totaling $38 million and boasts impressive management, board and advisory rosters.
Kinsa made its smartphone plug-in thermometer, the first cleared by FDA, available at several major consumer retailers including Apple and Amazon earlier this month. Now, in a move that's inverse to the usual order of events for med tech startups, the company has raised a $9.6 million Series A.
After taking the helm and pointing South San Francisco-based iPierian in a new direction, CEO Nancy Stagliano today unveiled a $30 million venture round designed to get her crew into the clinic with a lead antibody program, while a separate project is being spun out into a new biotech that she will also direct.
In the latest biotech business formed around a major drugmaker's assets, Atara Biotherapeutics has emerged with early-stage drug candidates against cancer and other serious diseases from biopharma behemoth Amgen.
San Diego-based Elcelyx Therapeutics is jumping out of stealth mode today with news that it has picked up an extended venture round, bringing its total venture backing to $20 million as the fledgling biotech pursues a new formulation of metformin as well as a dietary supplement.
This morning the biotech--which is backed by Google Ventures, Third Rock and Kleiner Perkins--announced that Novartis is expanding on their pact with plans to use the test to properly match patients to most of their Phase I and Phase II cancer trials over the next three years.
Kleiner Perkins Caulfield & Byers has closed the books on a new $525 million fund. And a chunk of that treasure is earmarked for early-stage life science companies.
A pair of high-profile venture investors has joined forces to finance a startup sequencing outfit that has some ambitious near-term marketing plans to start selling a test that can help match cancer
Kleiner Perkins Caufield & Byers' Chinese arm has reportedly struck a deal to invest $15 million in a biotech company located in the eastern region of the country. Quoting sources, Reuters said